Annual EBITDA
-$127.82 M
-$44.61 M-53.60%
31 December 2023
Summary:
Spyre Therapeutics annual earnings before interest, taxes, depreciation & amortization is currently -$127.82 million, with the most recent change of -$44.61 million (-53.60%) on 31 December 2023. During the last 3 years, it has fallen by -$63.75 million (-99.49%). SYRE annual EBITDA is now -1338.60% below its all-time high of -$8.88 million, reached on 01 December 2014.SYRE EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$55.39 M
-$11.24 M-25.47%
30 September 2024
Summary:
Spyre Therapeutics quarterly earnings before interest, taxes, depreciation & amortization is currently -$55.39 million, with the most recent change of -$11.24 million (-25.47%) on 30 September 2024. Over the past year, it has dropped by -$22.15 million (-66.62%). SYRE quarterly EBITDA is now -6371.03% below its all-time high of -$856.00 thousand, reached on 01 March 2014.SYRE Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$195.07 M
-$22.15 M-12.81%
30 September 2024
Summary:
Spyre Therapeutics TTM earnings before interest, taxes, depreciation & amortization is currently -$195.07 million, with the most recent change of -$22.15 million (-12.81%) on 30 September 2024. Over the past year, it has dropped by -$96.15 million (-97.21%). SYRE TTM EBITDA is now -22688.20% below its all-time high of -$856.00 thousand, reached on 01 March 2014.SYRE TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
SYRE EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -53.6% | -66.6% | -97.2% |
| 3 y3 years | -99.5% | -176.5% | -204.4% |
| 5 y5 years | -59.9% | -154.1% | -144.1% |
SYRE EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -99.5% | at low | -203.5% | at low | -204.4% | at low |
| 5 y | 5 years | -99.5% | at low | -778.3% | at low | -204.4% | at low |
| alltime | all time | -1338.6% | at low | -6371.0% | at low | <-9999.0% | at low |
Spyre Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$55.39 M(+25.5%) | -$195.07 M(+12.8%) |
| June 2024 | - | -$44.15 M(-7.6%) | -$172.92 M(+10.1%) |
| Mar 2024 | - | -$47.77 M(+0.0%) | -$157.12 M(+23.1%) |
| Dec 2023 | -$127.82 M(+53.6%) | -$47.75 M(+43.6%) | -$127.60 M(+29.0%) |
| Sept 2023 | - | -$33.24 M(+17.3%) | -$98.92 M(+17.9%) |
| June 2023 | - | -$28.34 M(+55.2%) | -$83.92 M(+8.4%) |
| Mar 2023 | - | -$18.26 M(-4.3%) | -$77.43 M(-6.9%) |
| Dec 2022 | -$83.21 M(+29.9%) | - | - |
| Dec 2022 | - | -$19.07 M(+4.5%) | -$83.21 M(-1.1%) |
| Sept 2022 | - | -$18.25 M(-16.5%) | -$84.18 M(-1.9%) |
| June 2022 | - | -$21.85 M(-9.1%) | -$85.80 M(+22.1%) |
| Mar 2022 | - | -$24.04 M(+20.0%) | -$70.26 M(+9.7%) |
| Dec 2021 | -$64.07 M(-20.4%) | -$20.03 M(+0.8%) | -$64.07 M(-3.6%) |
| Sept 2021 | - | -$19.88 M(+215.2%) | -$66.45 M(+3.1%) |
| June 2021 | - | -$6.31 M(-64.7%) | -$64.44 M(-18.9%) |
| Mar 2021 | - | -$17.85 M(-20.3%) | -$79.47 M(-1.3%) |
| Dec 2020 | -$80.48 M(+0.7%) | -$22.41 M(+25.4%) | -$80.48 M(+0.8%) |
| Sept 2020 | - | -$17.87 M(-16.2%) | -$79.88 M(-5.0%) |
| June 2020 | - | -$21.34 M(+13.1%) | -$84.05 M(+3.5%) |
| Mar 2020 | - | -$18.87 M(-13.5%) | -$81.23 M(+1.6%) |
| Dec 2019 | -$79.92 M | -$21.80 M(-1.1%) | -$79.92 M(+9.0%) |
| Sept 2019 | - | -$22.04 M(+19.0%) | -$73.35 M(+15.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2019 | - | -$18.52 M(+5.5%) | -$63.47 M(+16.4%) |
| Mar 2019 | - | -$17.56 M(+15.3%) | -$54.55 M(+20.8%) |
| Dec 2018 | -$45.17 M(+64.7%) | -$15.23 M(+25.2%) | -$45.17 M(+23.8%) |
| Sept 2018 | - | -$12.17 M(+26.8%) | -$36.50 M(+13.1%) |
| June 2018 | - | -$9.60 M(+17.4%) | -$32.26 M(+10.0%) |
| Mar 2018 | - | -$8.18 M(+24.6%) | -$29.32 M(+6.9%) |
| Dec 2017 | -$27.43 M(+26.0%) | -$6.56 M(-17.3%) | -$27.43 M(+4.0%) |
| Sept 2017 | - | -$7.93 M(+19.1%) | -$26.37 M(+6.7%) |
| June 2017 | - | -$6.66 M(+6.0%) | -$24.71 M(+5.1%) |
| Mar 2017 | - | -$6.28 M(+14.0%) | -$23.52 M(+8.0%) |
| Dec 2016 | -$21.77 M(+94.0%) | -$5.51 M(-12.1%) | -$21.77 M(+7.6%) |
| Sept 2016 | - | -$6.27 M(+14.7%) | -$20.23 M(+16.6%) |
| June 2016 | - | -$5.46 M(+20.4%) | -$17.36 M(+30.4%) |
| Mar 2016 | - | -$4.54 M(+14.4%) | -$13.31 M(+18.6%) |
| Dec 2015 | -$11.23 M(+26.3%) | -$3.97 M(+17.0%) | -$11.23 M(+7.7%) |
| Sept 2015 | - | -$3.39 M(+139.9%) | -$10.43 M(+2.5%) |
| June 2015 | - | -$1.41 M(-42.3%) | -$10.17 M(-3.0%) |
| Mar 2015 | - | -$2.45 M(-22.6%) | -$10.48 M(+18.0%) |
| Dec 2014 | -$8.88 M | -$3.17 M(+1.1%) | -$8.88 M(+55.4%) |
| Sept 2014 | - | -$3.13 M(+81.7%) | -$5.72 M(+121.5%) |
| June 2014 | - | -$1.73 M(+101.5%) | -$2.58 M(+201.5%) |
| Mar 2014 | - | -$856.00 K | -$856.00 K |
FAQ
- What is Spyre Therapeutics annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Spyre Therapeutics?
- What is Spyre Therapeutics annual EBITDA year-on-year change?
- What is Spyre Therapeutics quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Spyre Therapeutics?
- What is Spyre Therapeutics quarterly EBITDA year-on-year change?
- What is Spyre Therapeutics TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Spyre Therapeutics?
- What is Spyre Therapeutics TTM EBITDA year-on-year change?
What is Spyre Therapeutics annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of SYRE is -$127.82 M
What is the all time high annual EBITDA for Spyre Therapeutics?
Spyre Therapeutics all-time high annual earnings before interest, taxes, depreciation & amortization is -$8.88 M
What is Spyre Therapeutics annual EBITDA year-on-year change?
Over the past year, SYRE annual earnings before interest, taxes, depreciation & amortization has changed by -$44.61 M (-53.60%)
What is Spyre Therapeutics quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of SYRE is -$55.39 M
What is the all time high quarterly EBITDA for Spyre Therapeutics?
Spyre Therapeutics all-time high quarterly earnings before interest, taxes, depreciation & amortization is -$856.00 K
What is Spyre Therapeutics quarterly EBITDA year-on-year change?
Over the past year, SYRE quarterly earnings before interest, taxes, depreciation & amortization has changed by -$22.15 M (-66.62%)
What is Spyre Therapeutics TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of SYRE is -$195.07 M
What is the all time high TTM EBITDA for Spyre Therapeutics?
Spyre Therapeutics all-time high TTM earnings before interest, taxes, depreciation & amortization is -$856.00 K
What is Spyre Therapeutics TTM EBITDA year-on-year change?
Over the past year, SYRE TTM earnings before interest, taxes, depreciation & amortization has changed by -$96.15 M (-97.21%)